Enliven Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 6200 LOOKOUT ROAD, BOULDER, CO, 80301
Mailing Address 6200 LOOKOUT ROAD, BOULDER, CO, 80301
Phone 720-647-8519
Fiscal Year End 1231
EIN 811523849
Financial Overview
FY2024
-$71.58M
Net Income
$325.76M
Total Assets
$124.12M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | January 22, 2026 | View on SEC |
| 4 Insider stock transaction report | January 22, 2026 | View on SEC |
| 4 Insider stock transaction report | January 13, 2026 | View on SEC |
| 4 Insider stock transaction report | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
| 3 Initial insider ownership report | January 9, 2026 | View on SEC |
| 8-K Current report of material events | January 7, 2026 | View on SEC |
| 4 Insider stock transaction report | December 23, 2025 | View on SEC |
Insider Trading
STRONG SELL 4 insiders
20 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.